Pah - phenylalanine hydroxylase Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 24616

Summary

Enables several functions, including identical protein binding activity; iron ion binding activity; and phenylalanine 4-monooxygenase activity. Involved in L-phenylalanine metabolic process; protein hydroxylation; and tyrosine biosynthetic process, by oxidation of phenylalanine. Human ortholog(s) of this gene implicated in intellectual disability and phenylketonuria. Orthologous to human PAH (phenylalanine hydroxylase). [provided by Alliance of Genome Resources, Apr 2022]

Pah Products (1)

mRNA Protein Name
NM_012619.2 NP_036751.2 phenylalanine-4-hydroxylase

Gene Ontology

  • Molecular Function
  • Biological Process
Molecular Function GO Annotation Evidence Références Source
enables amino acid binding IDA
IDA: Inferred from direct assay
16953590 RGD
enables identical protein binding IPI
IPI: Inferred from physical interaction
10331871 RGD
enables iron ion binding IDA
IDA: Inferred from direct assay
10331871 RGD
enables phenylalanine 4-monooxygenase activity IDA
IDA: Inferred from direct assay
10839989 RGD
Biological Process GO Annotation Evidence Références Source
involved in L-phenylalanine metabolic process IDA
IDA: Inferred from direct assay
16953590 RGD
involved in protein hydroxylation IDA
IDA: Inferred from direct assay
16953590 RGD
involved in tyrosine biosynthetic process IDA
IDA: Inferred from direct assay
16953590 RGD
involved in tyrosine biosynthetic process, by oxidation of phenylalanine IDA
IDA: Inferred from direct assay
10839989 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

phenylalanine-4-hydroxylase

  • phe-4-monooxygenase

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (9)
Cat. No. Nom du produit Effect
Pureté Rare Diseases
HY-A0124A Sapropterin dihydrochloride 99.82% Yes
HY-14184 Macitentan 99.87% Yes
HY-P0012 Aviptadil Inhibitor 99.95% Unkown
HY-A0126A Epoprostenol sodium Inducer 98.03% Unkown
HY-P0012A Aviptadil acetate Inhibitor 99.87% Unkown
HY-109013 Sofpironium bromide Inhibitor 98.26% Unkown
HY-A0124AR Sapropterin dihydrochloride (Standard) 99.96% Unkown
HY-14184A Macitentan n-butyl analogue 99.35% Unkown
HY-A0124 Sapropterin / Unkown

Clinical Phase

Bioactive Molecules (9)
Cat. No. Nom du produit Effect
Pureté Phase
HY-A0126AR Epoprostenol sodium (Standard) / Phase 4
HY-109112 Brilaroxazine 98.82% Phase 3
HY-109190 Seralutinib Inhibitor 99.94% Phase 2
HY-15472 PRX-08066 97.46% Phase 2
HY-101124 Rodatristat ethyl Inhibitor 99.82% Phase 2
HY-15472A PRX-08066 maleate / Phase 2
HY-B1727 Phenanthrene 99.82% Phase 1
HY-129851 NTP42 Antagonist 98.58% Phase 1
HY-170435 PDE5-IN-13 Inhibitor / Phase 1
Bioactive MoleculesInhibitory Antibodies (2)
Cat. No. Nom du produit Effect
Pureté Phase
HY-P990733 Cibotercept Inhibitor 99.85% Phase 2
HY-P992008 PF-07868489 / Phase 2

Pre-clinical Phase

Bioactive Molecules (62)
Cat. No. Nom du produit
Effect
Pureté
Rare Diseases
HY-W011845 DMBA Inducer 99.94% Unkown
HY-15425 PF-543 99.85% Unkown
HY-15425A PF-543 Citrate 99.47% Unkown
HY-103609 Pyrene 99.83% Unkown
HY-W014075 1-Hydroxypyrene 99.38% Unkown
HY-161119 Drpitor1a Inhibitor 96.95% Unkown
HY-W026772 Fluorene 99.35% Unkown
HY-121107 Chrysene 99.81% Unkown
HY-Y1771 2-Carboxybenzaldehyde 99.95% Unkown
HY-111450 CB7993113 Antagonist 98.0% Unkown
HY-W016103 1-Hydroxy-2-naphthoic acid 99.70% Unkown
HY-W013570 Acenaphthylene 99.62% Unkown
HY-108464A Phenamil methanesulfonate Inhibitor 98.1% Unkown
HY-B1727S Phenanthrene-d10 99.46% Unkown
HY-134620 Cyanine 5 NHS ester tetrafluoroborate 98.0% Unkown
HY-14184S Macitentan-d4 99.85% Unkown
HY-N11222 Nonanoylcarnitine 99.87% Unkown
HY-W012278 Benz[a]anthracene Ligand 99.90% Unkown
HY-128593 TPN171 Inhibitor 98.10% Unkown
HY-121107S Chrysene-d12 99.71% Unkown
HY-W014075S 1-Hydroxypyrene-d9 99.95% Unkown
HY-177948 GRK2 degrader-1 Degrader 98.83% Unkown
HY-23498 Benzo[k]fluoranthene / Unkown
HY-RS09979 PAH Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W026772S Fluorene-d10 99.0% Unkown
HY-W026772S1 Fluorene-d8 / Unkown
HY-131973 PDE10A-IN-2 hydrochloride Inhibitor 98.43% Unkown
HY-174416 Smurf1-IN-5 Inhibitor / Unkown
HY-P3242 Mad1 (6-21) 98.02% Unkown
HY-Q43097 Hsp110-STAT3 PPI-IN-1 Inhibitor 90% Unkown
HY-120152A SLP7111228 hydrochloride Inhibitor 98.01% Unkown
HY-144856S1 Sapropterin-d3 / Unkown
HY-33451 4-Dibenzofurancarboxylic acid 99.92% Unkown
HY-W013570S Acenaphthylene-d8 99.48% Unkown
HY-W017708 Triphenylene 99.30% Unkown
HY-W777456 Phenanthrene-13C6 99.9% Unkown
HY-15425B PF-543 hydrochloride / Unkown
HY-109013S Sofpironium-13C,d3 bromide Inhibitor / Unkown
HY-115477 Brilaroxazine hydrochloride / Unkown
HY-121025 BUR1 Inhibitor 99.65% Unkown
HY-149492 Phosphatase-IN-1 Inhibitor 99.88% Unkown
HY-155737 ET receptor antagonist 1 Inhibitor / Unkown
HY-155738 ET receptor antagonist 2 Inhibitor / Unkown
HY-155739 ET receptor antagonist 3 Inhibitor / Unkown
HY-167849 Sofpironium tosylate Inhibitor / Unkown
HY-167906S Hexadecyl 2-((4-Nitrophenyl)thio)acetate-13C2 / Unkown
HY-168178 Hsp110-STAT3 PPI-IN-2 Inhibitor / Unkown
HY-170387 MRS8209 Antagonist / Unkown
HY-170419A APJ receptor agonist 10 free base Agonist 99.27% Unkown
HY-D1549 o-Pah / Unkown
HY-N10021 Benzo[e]pyrene 98.0% Unkown
HY-P3242A Mad1 (6-21) TFA / Unkown
HY-W777458 Fluorene-13C6 / Unkown
HY-W778162 Phenanthrene-13C2 / Unkown
HY-108936 QCC374 Agonist / Unkown
HY-167906 Lunamarine Inhibitor / Unkown
HY-172508 Perylene dU phosphoramidite / Unkown
HY-19197 2-NAP / Unkown
HY-RS17018 Pah Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23461 Pah Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W016103R 1-Hydroxy-2-naphthoic acid (Standard) / Unkown
HY-W585976 Benzo[a]pyrene diol epoxide / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Pah NCBI NCBI:5053